

# Marie Lindquist

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11240481/publications.pdf>

Version: 2024-02-01

23  
papers

2,295  
citations

535685

17  
h-index

721071

23  
g-index

28  
all docs

28  
docs citations

28  
times ranked

2060  
citing authors

#	ARTICLE	IF	CITATIONS
1	WHODrug: A Global, Validated and Updated Dictionary for Medicinal Information. Therapeutic Innovation and Regulatory Science, 2020, 54, 1116-1122.	0.8	23
2	Developing a Crowdsourcing Approach and Tool for Pharmacovigilance Education Material Delivery. Drug Safety, 2017, 40, 191-199.	1.4	13
3	Authors'™ Reply to Harpaz et al. Comment on: "Zoo or Savannah? Choice of Training Ground for Evidence-Based Pharmacovigilance". Drug Safety, 2015, 38, 115-116.	1.4	3
4	Teaching Pharmacovigilance: the WHO-ISO-P Core Elements of a Comprehensive Modular Curriculum. Drug Safety, 2014, 37, 743-759.	1.4	39
5	Clinical stories are necessary for drug safety. Clinical Medicine, 2014, 14, 326-327.	0.8	4
6	vigiGrade: A Tool to Identify Well-Documented Individual Case Reports and Highlight Systematic Data Quality Issues. Drug Safety, 2014, 37, 65-77.	1.4	137
7	Zoo or Savannah? Choice of Training Ground for Evidence-Based Pharmacovigilance. Drug Safety, 2014, 37, 655-659.	1.4	36
8	Social Media and Networks in Pharmacovigilance. Drug Safety, 2011, 34, 267-271.	1.4	43
9	Understanding and Communicating Key Concepts in Risk Management. Drug Safety, 2009, 32, 449-452.	1.4	8
10	VigiBase, the WHO Global ICSR Database System: Basic Facts. Drug Information Journal, 2008, 42, 409-419.	0.5	398
11	The Need for Definitions in Pharmacovigilance. Drug Safety, 2007, 30, 825-830.	1.4	44
12	Use of Triage Strategies in the WHO Signal-Detection Process. Drug Safety, 2007, 30, 635-637.	1.4	31
13	Data Quality Management in Pharmacovigilance. Drug Safety, 2004, 27, 857-870.	1.4	57
14	The authors' reply. Drug Safety, 2003, 26, 364-366.	1.4	10
15	Assessing the Impact of Drug Safety Signals from the WHO Database Presented in "SIGNAL". Drug Safety, 2003, 26, 721-727.	1.4	22
16	A Data Mining Approach for Signal Detection and Analysis. Drug Safety, 2002, 25, 393-397.	1.4	120
17	Signal Selection and Follow-Up in Pharmacovigilance. Drug Safety, 2002, 25, 459-465.	1.4	82
18	A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiology and Drug Safety, 2002, 11, 3-10.	0.9	822

#	ARTICLE	IF	CITATIONS
19	A Retrospective Evaluation of a Data Mining Approach to Aid Finding New Adverse Drug Reaction Signals in the WHO International Database. <i>Drug Safety</i> , 2000, 23, 533-542.	1.4	176
20	From association to alert—a revised approach to international signal analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 1999, 8, S15-S25.	0.9	12
21	From association to alert—a revised approach to international signal analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 1999, 8, S15-S25.	0.9	62
22	Risks of non-sedating antihistamines. <i>Lancet</i> , The, 1997, 349, 1322.	6.3	116
23	How Does Cystitis Affect a Comparative Risk Profile of Tiaprofenic Acid with Other Non-steroidal Antiinflammatory Drugs? An International Study Based on Spontaneous Reports and Drug Usage Data. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1997, 80, 211-217.	0.0	17